ALLIANCE PHARMA PLC

Board/Management Information • May 30, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5926P

Alliance Pharma PLC

30 May 2018

For immediate release	30 May 2018

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Directorate Change

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that Thomas Casdagli, a Non-Executive Director of the Company, has decided to step down from Alliance's Board after nine years. Mr Casdagli, a partner of MVM Life Science Partners LLP, will leave Alliance as of 30 May 2018.

David Cook, Alliance Pharma's Chairman, commented: "On behalf of the Board, I would like to thank Tom for his very significant contribution to Alliance over the past nine years. We wish him well for the future."

Thomas Casdagli added: "It has been a pleasure working with Alliance during my tenure on the Board. The Company has transformed over this period from a UK-focused established products business to a global pharmaceutical company with good organic and acquisitive growth prospects." 

For further information:

Alliance Pharma plc                                                                                 + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk 

Buchanan                                                                                                   + 44 (0) 20 7466 5000

Mark Court / Sophie Wills / Gemma Mostyn-Owen

Numis Securities Limited                                                                         + 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

Corporate Broking: James Black / Toby Adcock

Investec Bank plc                                                                                     +44 (0) 20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Rob Baker

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAFMGZKVLRGRZM